Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
MK-677: Evidence Summary
Evidence summary for MK-677 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to MK-677 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Growth hormone secretion | Tier B | 6 | Consistently raises GH and IGF-1 levels to youthful ranges in clinical trials |
| Muscle wasting / sarcopenia | Tier C | 3 | Improved lean mass in elderly subjects but mixed functional outcomes |
| Sleep quality | Tier C | 2 | Increased REM and stage IV sleep duration in healthy volunteers |